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Description
Consumption of veterinary antimicrobials in food-producing animal species in Finland is low and in recent 
years, has decreased further. Drop is noted in sales of almost all antimicrobial classes. Particularly sales of 
orally administered products have decreased. Sales of tablets intended to companion animals has almost 
halved during this decade. Majority, two thirds, of all antimicrobial products sold in 2018 was for treatment 
of individual animals and the remaining third products applicable for group treatment. Narrow spectrum 
penicillin G was the most used antimicrobial for animals and the proportion of highest priority critically 
important antimicrobials (HPCIA) was very low.
The antimicrobial resistance situation in bacteria from animals and food has remained relatively good in 
Finland. However, in certain bacteria resistance was detected in moderate or high levels. Therefore, there is 
a need to further emphasise the preventive measures and prudent use of antimicrobials. It is important to 
follow the Finnish recommendations for the use of antimicrobials in animals.
Among salmonella and campylobacter isolated from Finnish food-producing animals, resistance levels 
were mainly low. For the first time in Finland, multidrug resistant S. Kentucky was isolated from cattle in 
2018. From 2014, the occurrence of fluoroquinolone and tetracycline resistance in campylobacter from 
broilers have varied. The occurrence of fluoroquinolone resistance in indicator E. coli has increased 
although the resistance is still low. Among pathogenic bacteria isolated from food-producing animals the 
most notifiable change was the worsening of resistance in some bovine respiratory disease pathogens. 
In other pathogens from food-producing animals the resistance situation remained similar as in previous 
years.
The proportion of resistant bacterial isolates from companion animals and horses decreased for nearly all 
antimicrobials. However, the proportion of resistant isolates is still high for some antimicrobials.
ESBL/AmpC-producing bacteria were still encountered in broilers and broiler meat; prevalence of these 
bacteria in broiler meat was somewhat lower in 2018 compared to 2016.
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Tiivistelmä
Kuvailulehti
Tuotantoeläinten mikrobilääkkeiden myynti Suomessa on vähäistä ja viime vuosina se on vähentynyt 
edelleen. Myynti on laskenut lähes kaikissa lääkeryhmissä. Varsinkin suun kautta annettavia valmisteita 
myytiin aikaisempaa vähemmän. Seuraeläinten tablettien myynti on lähes puolittunut tällä vuosikymmenellä. 
Valtaosa, kaksi kolmannesta, vuonna 2018 myydyistä eläinten mikrobilääkkeistä oli tarkoitettu yksilölääkintään 
ja loppukolmannes eläinryhmien hoitoon. Kapeakirjoinen penisilliini oli eläinten käytetyin mikrobilääkeaine ja 
ihmisten lääkinnässä kriittisen tärkeiden mikrobilääkkeiden (HPCIA) osuus oli erittäin vähäinen.
Eläimistä ja elintarvikkeista eristettyjen bakteerien mikrobilääkeresistenssitilanne Suomessa on edelleen 
suhteellisen hyvä. Joillakin bakteereilla resistenssiä kuitenkin esiintyy kohtalaisesti tai yleisesti, joten eläinten 
mikrobilääkkeiden käyttötarpeen vähentämiseen ja hallittuun mikrobilääkkeiden käyttöön tulee edelleen 
kiinnittää huomiota. Eläimille annettuja mikrobilääkkeiden käyttösuosituksia on syytä noudattaa.
Kotimaisista tuotantoeläimistä eristetyillä salmonelloilla ja broilereista eristetyillä kampylobakteereilla 
resistenssiä todettiin pääasiassa vähän. Vuonna 2018 suomalaisilta naudoilta todettiin ensimmäisen 
kerran useassa muussakin Euroopan maassa esiintyvä moniresistentti Salmonella Kentucky. Vuodesta 2014 
alkaen broilereista eristetyillä kampylobakteereilla on todettu vaihtelevasti resistenssiä fluorokinoloneille 
ja tetrasykliinille. Myös broilereista eristetyillä E. coli -indikaattoribakteereilla fluorokinoloniresistenssin 
esiintyminen on lisääntynyt, vaikka resistenssi on vielä vähäistä. Tuotantoeläimille tautia-aiheuttavien 
patogeenien resistenssitilanteen kannalta merkittävin muutos aiempiin vuosiin verrattuna oli joidenkin 
nautojen hengitystiepatogeenien resistenssitilanteen huonontuminen. Muuten tuotantoeläinten patogeenien 
resistenssitilanteessa ei todettu merkittäviä muutoksia.
Seura- ja harrastuseläimistä eristettyjen bakteerien joukossa resistenssi väheni seurantajakson aikana lähes 
kaikkien mikrobilääkkeiden suhteen. Tietyille mikrobilääkkeille resistenttien kantojen osuus on kuitenkin vielä 
korkea.
ESBL/AmpC-bakteereita esiintyi edelleen broilereilla ja broilerinlihassa; esiintyvyys broilerinlihassa oli hieman 
alhaisempi vuonna 2018 vuoteen 2016 verrattuna.
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Referat
Försäljningen av antimikrobiella läkemedel för produktionsdjur i Finland är låg och har minskat ytterligare 
under de senaste åren. Försäljningen har minskat i nästan alla läkemedelsgrupper. I synnerhet preparat 
som administreras oralt såldes mindre än tidigare. Försäljningen av tabletter för sällskapsdjur har minskat 
med nästan hälften under detta decennium. Största delen, två av tre antimikrobiella läkemedel för djur som 
såldes år 2018 var avsedda för medicinering av individer och en tredjedel för behandling av djurgrupper. Det 
mest använda antimikrobiella medlet som användes för djur var penicillin med smalt spektrum, och andelen 
antimikrobiella läkemedel (HPCIA) som är kritiskt viktiga i humanmedicin var mycket låg.
Resistenssituationen hos bakterier som har isolerats från djur och livsmedel av animaliskt ursprung har hållits 
relativt god i Finland. Hos vissa bakterier var förekomsten av resistens ändå måttlig eller vanlig. Därför måste 
uppmärksamhet ägnas åt att minska behovet av att använda antimikrobiella medel för djur och kontrollerad 
användning av antimikrobiella medel. Det är viktigt att följa rekommendationerna för användning av 
antimikrobiella medel för djur.
Hos salmonellabakterier som isolerats från inhemska livsmedelsproducerande djur och campylobakterier som 
isolerats från broilrar påvisades huvudsakligen endast litet resistens. År 2018 påvisades den multiresistenta 
Salmonella Kentucky för första gången hos finländska kor. Den förekommer även i flera andra länder i Europa. 
Sedan 2014 har varierande resistens mot fluorokinoloner och tetracykliner påvisats hos campylobakterier 
som isolerats från broilrar. Förekomsten av resistens mot fluorokinoloner hos E. coli -indikatorbakterier som 
isolerats från broilrar har också ökat även om resistens var ändå mattlig. Bland patogener isolerade från 
livsmedelsproducerande djur mest anmärkningsvärd ändring har skett i patogener från lunginflammation hos 
kalvar där resistens-situation har försämrats. Annars konstaterades inga särskilda förändringar.
Hos bakteriestammar som isolerats från hundar, katter och hästar minskade resistensen för så gott som alla 
antibiotika. För vissa läkemedel är andelen resistenta stammar trots allt fortfarande hög.
 
ESBL/AmpC-bakterier förekom fortfarande hos broilrar och i broilerkött; förekomsten i broilerkött var något 
lägre år 2018 jämfört med år 2016.
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Introduction 
 
 
 
 
The occurrence of antimicrobial resistance in bacteria from animals in Finland has been screened already in 
the 1980’s starting with salmonella isolates from food-producing animals. The regular annual antimicrobial 
resistance monitoring programme, FINRES-Vet, started in 2002 and includes resistance surveillance of 
zoonotic and indicator bacteria as well as of certain animal pathogens. Currently, resistance is monitored as 
required by the Commission Implementing Decision 2013/652/EU and as decided at the national level.  
 
Resistance monitoring of zoonotic bacteria is of uttermost importance as they can be transmitted between 
animals and humans, creating a direct threat to human health. Also, monitoring the resistance situation in 
animal pathogens is vital for revealing putative emerging resistance traits as well as indicating the 
effectiveness of antimicrobial treatment in veterinary medicine. However, it must be emphasized that when 
assessing the overall resistance levels of pathogenic bacteria isolated from clinical cases, data may be biased 
because the isolates are frequently obtained from severe or recurrent infections. 
 
The resistance of indicator bacteria in a given population reflects the selection pressure caused by the use of 
antimicrobials. The indicator bacteria constitute the major component of intestinal microbiota and their 
genomes can also function as a reservoir for resistance genes, which may be transferred to pathogenic 
bacteria. 
 
FINRES-Vet programme has the following objectives:  
• to monitor the consumption of antimicrobial agents used in veterinary medicine, 
• to monitor the resistance to antimicrobial agents in bacteria from the major food-producing 
animals, food and pets, 
• to analyse trends in the occurrence of resistant bacteria from animals and food,  
• to monitor the emergence of resistant clones and the appearance of new resistance phenotypes 
in bacteria from the afore-mentioned sources. 
 
The previous FINRES-Vet reports have presented an overall favorable resistance situation among bacteria 
isolated from animals and food of animal origin in Finland. This is probably the positive outcome of the strict 
policy; antimicrobial drugs for treating animals are prescribed only by veterinarians and no profit can be 
made from their sales. However, the increase in the occurrence of multidrug resistant bacteria in food-
producing animals and the resistance in some animal pathogens is of growing concern indicating that there 
is a need to further emphasise the preventive measures and prudent use of antimicrobials for animals. 
Recommendations for antimicrobial usage in the major infectious diseases of animals have been established 
to promote prudent use. These recommendations have been updated in 2016 and can be found in the 
internet site of Finnish Food Authority (ruokavirasto.fi or foodauthority.fi).  
 
This eighth FINRES-Vet report includes new monitoring data from the year 2018. Also, data from previous 
years have been included to aid in interpreting trends in the occurrence of resistance.  The report covers 
resistance results of indicator bacteria (non-pathogenic E. coli from poultry), zoonotic bacteria (salmonella 
from food-producing animals and campylobacter from poultry), and several animal pathogens from the main 
food-producing animal species (pigs, cattle, poultry), fur animals, companion animals (dogs, cats) and horses. 
In addition, the results of the specific monitoring of extended-spectrum beta-lactamase producing E. coli 
from poultry and poultry meat is included. 
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The FINRES-Vet programme is coordinated and the antimicrobial resistance in bacteria from food-producing 
animals is monitored by the Finnish Food Authority Ruokavirasto (former Evira). The sales of antimicrobial 
agents for veterinary use is monitored by Finnish Medicines Agency Fimea, and the use of feed additives and 
medicated feeds by Ruokavirasto. The Clinical Microbiology Laboratory of the Faculty of Veterinary Medicine 
(University of Helsinki) provides antimicrobial susceptibility data from companion animals and horses. 
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1 Use of therapeutic antimicrobials and feed additives for animals in 
Finland 
 
 
 
1.1 Changes in animal population 
 
Changes in the number of food-producing animals from 2017 to 2018 were relatively small. The decreasing 
trend in the number of pigs continued; 8% from 2017 to 2018. A slow annual increase in the number of 
poultry is also seen (Figure 1). Details on the number of holdings, live animals, and meat and milk production 
are presented in Appendix 1. The number of livestock and the number of animals slaughtered is used to 
calculate animal population, which is described using Population Correction Unit (PCU). Since 2010, the PCU 
has decreased from 520 to 500 (thousand tons). PCU of pigs has decreased the most. At the same time PCU 
of poultry has increased steadily. 
 
Figure 1. Changes in food-producing animal populations in Finland in 2010-2018, expressed in PCU. Detailed data on 
the PCU of food-producing animals in a tabulated form is presented in Appendix 1. 
 
Regarding the number of companion animals, Statistics Finland estimated that the number of dogs and cats 
in 2012 was 630 000 and 592 000, respectively. In 2016, the number of dogs had been estimated to have 
increased slightly to 700 000 while the number of cats remained stable. 
1.2 Therapeutic antimicrobials 
 
1.2.1 Background 
 
Finnish medicines agency Fimea monitors the sales of veterinary antimicrobials based on statistics obtained 
from pharmaceutical wholesalers. Sales data reported as kilograms of active ingredient is available since 
1995. This report includes data for 2010-2018, for a review of data for 1995-2009 see the FINRES-Vet reports 
covering the corresponding years.  
In 2010, sales data collection of veterinary antimicrobials in Finland was harmonised with the protocol of 
European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) project (EMA, 2019). Data covers 
also veterinary antimicrobials sold with special licence (exemption from marketing authorisation, i.e. 
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veterinary antimicrobial products obtained from another Member State and permitted to be marketed for 
specific animal species). As a deviation from the ESVAC-protocol, human medicinal products sold with special 
licence for use in animals are included although their sales are very low.  
Sales data are presented as kilograms of active ingredient for overall sales and sales by different 
administration routes i.e. injectables, orally administered antimicrobials and intramammaries. For 
intramammaries also sales of tubes per cow is reported. 
In order to compare changes in annual sales of antimicrobials, the data is linked to the number of animals. 
To estimate the numbers of food-producing animals, a population correction unit (PCU) is used. PCU is strictly 
a technical unit which corresponds approximately to one kg and gives an estimate of livestock and 
slaughtered animals in a given year. PCU has been developed within the ESVAC project and a detailed 
description of PCU calculation is available in ‘Trends in the sales of veterinary antimicrobial agents in nine 
European countries: Reporting period 2005-2009‘ (EMA, 2011).  
PCU-adjusted sales, reported as mg active ingredient per PCU, are in this report presented for the EU-
indicators of veterinary antimicrobial consumption i.e. overall sales, sales of fluoroquinolones and 3rd 
generation cephalosporins (ECDC, EFSA and EMA, 2017). Note that PCU-corrected data does not include 
tablets, as they are almost exclusively used in companion animals. As only estimates of the population of 
dogs and cats in Finland are available, sales of tablets cannot be adjusted to the population of companion 
animals, and therefore, sales of tablets are presented in a separate figure, as kg active ingredient. 
1.2.2 Overall sales (kg active ingredient) 
 
Total sales of veterinary antimicrobials show a decreasing trend from 2010 (Figure 2). In 2018, the total sales 
were 10 157 kg which is almost a quarter less than five years earlier. Sales have decreased in almost all 
antimicrobial classes and particularly in orally administered products.  
 
 
Figure 2. Overall sales (kg active ingredient) by class. Other betalactams = aminopenicillins, cephalosporins and 
cloxacillin. Others = pleuromutilines and amphenicol. Detailed data in a tabulated form is presented in Appendix 2. 
 
Two thirds of all antimicrobial products sold in 2018 were for treatment of individual animals (injectables, 
tablets, oral pastes and intramammaries) and the remaining third were products applicable for group 
treatment (premixes, oral powders and oral solutions) (Figure 3).  
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Figure 3. Proportioned sales of veterinary antimicrobials by form in 2018. Group treatment= premixes, oral solutions 
and oral powders. 
 
Benzylpenicillin was the most sold antimicrobial with 40% of the overall sales followed by tetracyclines (22%) 
and the combination of sulfonamides and trimethoprim (17%) (Figure 2.). Three antimicrobial groups of the 
WHO list of highest priority critically important antimicrobial classes in human medicine (HPCIA) are 
authorised for use in animals in Finland. These are macrolides, fluoroquinolones and 3rd generation 
cephalosporins. The proportion of sales for these remained low to extremely low (macrolides 4%, 
fluoroquinolones 0.8% and 3rd generation cephalosporins 0.005%). 
1.2.3 Sales based on route of administration (kg active ingredient) 
 
Over half of the antimicrobials sold were products administered as injections to animals (Figure 3). 
Benzylpenicillin remained the most sold injectable with a 74% proportion of all injectables despite a 10% 
decrease in sales in five years (Figure 4). Several factors have probably contributed to this change. The large-
scale shortage of benzylpenicillin products in Finland in 2015-2016 caused a decrease in the sales of 
benzylpenicillin. An additional factor could be the continuously declining number of sows and pigs. 
Benzylpenicillin is also the most important antimicrobial in the treatment of lactating cows, the number of 
which has decreased through this decade. 
 
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
Figure 4A and 4B. Trends in sales of injectable veterinary antimicrobials (4A) and sales of orally administered 
veterinary antimicrobials (4B). Other injectables = amphenicols, aminoglycosides and cephalosporins, Other oral 
products = amphenicols, aminoglycosides and pleuromutilins. Detailed data in a tabulated form is presented in 
Appendix 2. 
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Sales of orally administered products have decreased markedly in five years (Figure 4B). Reduced sales are 
seen for almost all antimicrobial classes, but the most notable changes were for combinations of sulfonamide 
and trimethoprim (-45% in five years) and for 1st generation cephalosporin (-73% since 2011). 
The majority of sulfonamide and trimethoprim combinations is used for several food-producing animal 
species and therefore it is not possible to conclude what is causing the changes in sales from the sales data 
alone. By contrast the 1st generation cephalosporins are authorized solely for companion animals. Prudent 
use guidance has traditionally been targeted to treatment of food-producing animals but during this decade 
greater emphasis was placed on companion animals. As a result, the sales of veterinary antimicrobial tablets 
have dropped by almost half since 2011. In addition to 1st generation cephalosporins, a decreasing trend is 
noted for sales of aminopenicillin and fluoroquinolone tablets (Figure 5). Note that sulfonamide and 
trimethoprim combination tablets were withdrawn from the market in 2015 and thereafter they have been 
available on special licence (exemption from marketing authorisation, i.e. antimicrobial products obtained 
from another Member State and permitted to be marketed for specific animal species).  
Detailed statistics on the number of companion animals are not available but it has been estimated that the 
number of dogs and cats has somewhat increased during this decade (Statistics Finland, 2016). In addition, 
there is no information on the number of human antimicrobials prescribed for companion animals. This data 
is not captured by the current data collection method, however, the amount is anticipated to be modest, as 
legislation requires veterinarians to prescribe veterinary medicinal products if they are available. 
 
 
Figure 5. Sales of antimicrobials tablets to companion animals (kg active ingredient) by class. Note that sulfonamide 
and trimethoprim combination tablets were withdrawn from the market in 2015. 
 
Sales of intramammary products for cows during lactation per cow has decreased through this decade 
whereas their use in dry cow therapy has somewhat increased (Figure 6).  
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Figure 6. Sales of antimicrobial tubes for intramammary use per cow during lactation period (blue column) and for dry 
cow period (red column) and the number of dairy cows (green curve). 
 
 
1.2.4 EU-indicators of antimicrobial consumption in food-producing animals (mg/PCU) 
 
ECDC, EFSA and EMA have jointly established a list of indicators to assist EU Member States in assessing their 
progress in reducing the use of antimicrobials and occurrence of AMR in both humans and food-producing 
animals. For food-producing animals, the indicators for antimicrobial consumption are: overall sales of 
veterinary antimicrobials, sales of 3rd and 4th generation cephalosporins, sales of quinolones (specifying the 
proportion of fluoroquinolones) and sales of polymyxins, measured in mg/PCU (ECDC, EFSA ja EMA 2017). Of 
these, overall sales of veterinary antimicrobials, sales of 3rd generation cephalosporins and sales of 
fluoroquinolones measured in mg/PCU are applicable in Finland.  
All EU-indicators of antimicrobial consumption in food-producing animals show similar results: the 
consumption of veterinary antimicrobials in food-producing animal species in Finland is very low (Table 1). In 
2018 overall sales was 18 mg/PCU, representing 1 mg/PCU (6 %) decrease from 2017 and 4 mg/PCU (19 %) 
decrease from 2014. National legislation in force since 1949 prohibits veterinarians to profit from 
antimicrobial sales. The same legislation also provides that antimicrobials are prescription-only-medicines 
(www.ruokavirasto.fi/en/AMRmilestones). Finland also has a long history of promoting the health and 
welfare of food-producing animals and is free of several important animal diseases. Prudent use guidelines 
have been available since 1996 and have been updated three times, last in spring 2016. 
Sales of 3rd generation cephalosporins have decreased significantly from an already extremely low level to 
close to zero (table 1). Decline since the peak year 2011 was 94%, and 9% from 2017. The major contributor 
to this change is presumably the control measures targeted towards those veterinarians using the highest 
amounts of these antimicrobials. Another factor is the prerequisite of susceptibility testing before using 
HPCIAs, introduced to the national law in 2014. A decreasing overall trend from 2014 is noted also for sales 
of fluoroquinolones. 
 
Table 1. EU-indicators of antimicrobial consumption in food-producing animals (mg/PCU) in Finland. Note that sales of 
tablets are excluded as they are used almost exclusively to companion animals. 
 Sales (mg/PCU) 2010 2011 2012 2013 2014 2015 2016 2017 2018 
Overall 23 22 22 22 22 20 19 19 18 
Fluoroquinolones  0.15 0.16 0.16 0.16 0.18 0.14 0.15 0.12 0.13 
3rd generation cephalosporins  0.009 0.017 0.029 0.016 0.016 0.014 0.006 0.001 0.001 
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1.3 Coccidiostats and antimicrobial feed additives 
 
Finnish Food Authority monitors the annual consumption of feed additives by collecting data from feed 
manufacturers. In Finland, the coccidiostats monensin natrium and narasin are used as prophylactic anti-
parasitic agents mainly in broiler and turkey production. In 2018, another coccidiostat, lasalocid sodium, has 
also been used. The overall use of coccidiostats has increased from 2005 to 2016 but has since been slightly 
decreasing (Table 2). 
 
 
Table 2. The use of coccidiostats, antimicrobial feed additives and other substances in feed in Finland in 2005 and 
2010-2018 (kg active substance/year). 
Substance 2005 2010 2011 2012 2013 2014 2015 2016 2017 2018 
   Coccidiostats  
Decoquinate 0 0 0 0 0 0 0 0.1 0 0 
Diclazuril 0 0 0 0 0 0 0 0 0.8 0.5 
Lasalocid sodium 0 1.4 0 0 0 0 0 0 0 1336 
Madmuramycin ammonium 1.5 0 0 0 0 0 0 0 0 0 
Monensin natrium 1 8669 6801 5837 7300 4614 6677 12640 15373 14693 5097 
Narasin 3204 5859 7658 6567 9626 9022 5478 5026 4918 13154 
Salinomycin 2 374 3 1170 4 495 0 0 0 0 0 0 0 
Robenidine hydrochloride 0 0 0 0 0 0 0 0 0 0 
   Antimicrobial feed additives 
Avoparcin 0 0 0 0 0 0 0 0 0 0 
Flavomycin 0 0 0 0 0 0 0 0 0 0 
Carbadox 0 0 0 0 0 0 0 0 0 0 
Olaquindox 0 0 0 0 0 0 0 0 0 0 
   Other substances 
Amprolium (and ethopabate) 0 0 0 0 0 0 0 0 0 0 
Dimetridazole 0 0 0 0 0 0 0 0 0 0 
Nifursol 0 0 0 0 0 0 0 0 0 0 
Total 12249 13832 13991 13867 14240 15699 18117 20399 19613 18587 
1 13.2 kg, 2 190 kg, 3 121 kg and 4 58 kg used in exported feed mixtures  
FINRES-Vet 2018 
Finnish Veterinary Antimicrobial Resistance Monitoring and Consumption of Antimicrobial Agents 
 
 
 
 
 
12 (42) 
2 Antimicrobial resistance in zoonotic bacteria 
 
 
 
 
2.1 Salmonella enterica in food-producing animals and domestic food 
 
The prevalence of Salmonella spp. in cattle, pigs and poultry as well as in meat and eggs is monitored through 
the national Salmonella control programme (23/EEO/1995; 20/EEO/2001, 1172/2009, 1173/2009). The 
objective of the programme is to maintain the annual incidence of salmonella contamination among food-
producing animals and in the respective meat and eggs at 1% or below. As a results, salmonella is rare in 
food-producing animals and foods of animal origin in Finland. Salmonella isolates from the control 
programme are tested for antimicrobial susceptibility and included in the FINRES-Vet programme. Isolates 
from clinical cases and domestic food industry’s in-house control systems are also included. Details of the 
susceptibility testing as well as correspondences between the verbal descriptions of the resistance levels and 
the actual percentage categories are described in Appendix 3. 
 
In 2018, 43 Salmonella enterica spp. enterica isolates from food-producing animals (including carcass 
samples) were tested for susceptibility. Most of the isolates (n=31) originated from cattle. Ten isolates 
originated from pigs and two isolates from Gallus gallus. The most common serotypes detected were S. 
Typhimurium (n=22), S. Enteritidis (n=6) and S. Kentucky (n=4). Other serotypes are shown in Appendix 4. 
Also, one S. Agama from a food sample containing bovine meat was discovered.  
 
Resistance in salmonella from food-producing animals was overall low (Table 3). In 2018, multi-resistant 
S. Kentucky was found in one dairy farm and three calf rearing farms which had bought calves from the 
positive dairy farm. S. Kentucky isolates were resistant to ampicillin, ciprofloxacin, gentamicin, nalidixic acid, 
sulfamethoxazole and tetracycline. This was the first time multi-resistant S. Kentucky was found among food-
producing animals in Finland. Multidrug resistance in salmonella isolated from Finnish food-producing 
animals has overall been very rare (Figure 7). 
 
Table 3. Distribution of MICs for Salmonella enterica in food-producing animals in 2018 (n=43). 
Substance %R 95% C.I. 
Distribution (%) of MICs (mg/L) 
0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048 
Ampicillin 9.3 3.7-21.6       65.1 25.6      9.3     
Azithromycin ND -         67.4 30.2 2.3        
Cefotaxime 0 0.0-8.2     100              
Ceftazidime 0 0.0-8.2      86.0 14.0            
Chloramphenicol 0 0.0-8.2          100         
Ciprofloxacin 9.3 3.7-21.6 39.5 48.8 2.3       4.7 4.7        
Colistin 2.3 0.4-12.1       79.1 18.6 2.3          
Gentamicin 9.3 3.7-21.6      76.7 14.0    7.0 2.3       
Meropenem 0 0.0-8.2                   
Nalidixic acid 9.3 3.7-21.6         88.4 2.3     9.3    
Sulfamethoxazole 9.3 3.7-21.6          2.3 55.8 27.9 4.7     9.3 
Tetracycline 9.3 3.7-21.6        90.7      9.3     
Tigecycline ND -     81.4 18.6             
Trimethoprim 0 0.0-8.2     83.7 14.0 2.3            
Bold vertical lines indicate epidemiological cut-off values for resistance. Hatched fields denote range of dilutions tested for each substance. Values above the range 
denote MIC values greater than the highest concentration in the range. MICs equal to or lower than the lowest concentration tested are given as the lowest 
concentration. ND, not determined 
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Figure 7. The number of sensitive and resistant salmonella isolates from food-producing animals in Finland in 2010-
2018. Numbers of isolates tested each year in brackets. 
 
 
2.2 Campylobacter spp. in food-producing and fur animals 
 
In 2018, Campylobacter jejuni isolates from broilers were obtained from the national Campylobacter control 
programme and C. jejuni from fur animals were isolated from diarrhea samples sent to the Finnish Food 
Safety Authority Evira. 
 
2.2.1 Campylobacter jejuni from broilers 
 
Within the national Campylobacter control programme in broilers, 55 C. jejuni isolates were tested for 
susceptibility in 2018. Of these, 14 (25%) were resistant to quinolones (ciprofloxacin, nalidixic acid) but 
resistance to the other studied antimicrobials was not detected (Table 4).  
 
Table 4. Distribution of MICs for Campylobacter jejuni from broilers in 2018 (n=55). 
Substance %R 95% C.I. 
Distribution (%) of MICs (mg/L) 
≤0.12 0.25 0.5 1 2 4 8 16 32 64 128 >128 
Ciprofloxacin 25.5 15.8-38.3  5.5 1.8    16.4 9.1     
Erythromycin 0 0.0-6.5    96.4 3.6        
Gentamicin 0 0.0-6.5  32.7 65.5 1.8         
Nalidixic acid 25.5 15.8-38.3     5.5 60 9.1    25.5  
Streptomycin 0 0.0-6.5  1.8 12.7 56.4 27.3 1.8       
Tetracycline 0 0.0-6.5   100          
Bold vertical lines indicate epidemiological cut-off values for resistance. Hatched fields denote range of dilutions tested for each substance. Values above the range 
denote MIC values greater than the highest concentration in the range. MICs equal to or lower than the lowest concentration tested are given as the lowest 
concentration. 
 
Antimicrobial resistance in Campylobacter jejuni from broilers at slaughter has been monitored 
systematically since 2003. Resistance levels in C. jejuni have been quite stable until the year 2013 and the 
occurrence of resistant isolates has been mainly at a low level (Figure 8). However, quinolone-resistant 
isolates have been more commonly detected since the year 2013. Between 2014 and 2018, the occurrence 
of quinolone resistance has been more common every other year with the previous high peak (25%) observed 
in 2014 and a smaller peak (8%) in 2016. The number of tetracycline resistant isolates peaked also in the 
same years and they were commonly also quinolone-resistant. However, in 2018, tetracycline resistance was 
not observed. The proportion of isolates resistant to erythromycin, gentamicin or streptomycin has remained 
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low or non-existent throughout the surveillance period. Further, the percentage of isolates susceptible to all 
studied antimicrobials has varied between 75%-100%, with the lowest percentage in 2014 and 2018 co-
incidencing the highest occurrence of quinolone resistance (Figure 9). Multidrug resistant isolates to the 
tested antimicrobials have not been detected. 
 
 
 
Figure 8. The proportions of resistant Campylobacter jejuni isolates from broilers at slaughter in Finland between the 
years 2007 and 2018. Numbers of isolates tested each year in brackets. 
 
 
 
Figure 9. Antimicrobial susceptibility of Campylobacter jejuni isolated from broilers at slaughter in Finland between the 
years 2007 and 2018. Numbers of isolates tested each year are the same as in Figure 8. 
 
 
2.2.2 Campylobacter jejuni from fur animals 
 
Campylobacter spp. are isolated from fur animals as part of diarrhea examination. Campylobacter jejuni 
infections in fur animals are treated with antimicrobials and these bacteria pose also a risk to the farmers. 
Isolates are mostly from farmed fox and to a lesser extent from mink. 
 
In 2018, the occurrence of resistance was moderate against quinolones and low against tetracycline and 
streptomycin (Table 5). Compared to year 2016, resistance to ciprofloxacin has decreased almost 4 
percentage points, and resistance to tetracycline about 30 percentage points. 
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Table 5. Distribution of MICs for Campylobacter jejuni from fur animals in 2018 (n=62). 
Substance %R 95% C.I. 
Distribution (%) of MICs (mg/L) 
≤0.12 0.25 0.5 1 2 4 8 16 32 64 128 >128 
Ciprofloxacin 12.9 6.7-23.4 85.5 1.6    1.6 9.7 1.6     
Erythromycin 0.0 0.0-5.8    100         
Gentamicin 0.0 0.0-5.8  37.1 53.1 4.8         
Nalidixic acid 12.9 6.7-23.4     8.1 62.9 16.1   1.6 11.3  
Streptomycin 1.6 0.3-8.6  1.6 6.5 64.5 24.2 1.6  1.6     
Tetracycline 8.1 3.5-17.5   91.9     3.2 1.6 3.2   
Bold vertical lines indicate epidemiological cut-off values for resistance. Hatched fields denote range of dilutions tested for each substance. Values above the range 
denote MIC values greater than the highest concentration in the range. MICs equal to or lower than the lowest concentration tested are given as the lowest 
concentration.  
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3 Screening for ESBL-, AmpC- and carbapenemase-producing 
Escherichia coli from food-producing animals and meat 
 
 
 
 
Screening of extended-spectrum beta-lactamase producing E. coli from food-producing animals and meat 
thereof is part of the harmonised monitoring in all EU member states (Comission Decision 2013/652/EU). In 
Finland, these bacteria are screened from broilers, cattle and pigs, as well as meat thereof, targeting broilers 
and broiler meat in 2018. Additionally, liners from the transport boxes of imported broiler and turkey 
parental flocks for meat production as well as of imported chicken parental flocks for egg production are 
screened annually. The details of the methodology are described in Appendix 3. 
3.1 ESBL/AmpC- and carbapenemase-producing E. coli in broilers and broiler meat 
 
In 2018, extended-spectrum beta-lactamase (including AmpC beta-lactamase) producing E. coli were 
screened from broiler caecal samples (n=289) collected at slaughterhouses and from broiler meat (n=300) 
collected at retail. From broilers, ESBL- or AmpC-producing E. coli was isolated from 13.1% (38/289) of the 
caecal samples in 2018 (Table 6). The prevalence of ESBL/AmpC-producing E. coli in broilers is at the same 
level as in 2016 and has increased compared to year 2014 when these bacteria were isolated from 7% of the 
samples, however using somewhat different method (different enrichment broth) for isolation (FINRES-Vet 
2013-2015). Details of the methodology is described in Appendix 3. 
  
All screened broiler meat samples have been of domestic origin, fresh and without added ingredients. In 
2018, ESBL- or AmpC-producing E. coli were isolated from 15.3% (46/300) of the samples (Table 6), which is 
approximately 7 percentage points less than in 2016. No carbapenemase-producing E. coli was detected in 
broilers or broiler meat.  
 
Table 6. Results of the specific screening of ESBL-, AmpC- and carbapenemase-producing E. coli in broilers and broiler 
meat in 2016 and 2018. 
Year Source 
Sampling 
stage 
Nr of 
samples 
Nr (%) 
of ESBL1 
Nr (%) 
of AmpC1 
Nr  
of CP-EC2 
% ESBL/AmpC 
2016 Broiler at slaughter 306 11 (3.6%)3 33 (11.1%) 0 14.4% 
2018 Broiler at slaughter 289 5 (1.7%) 33 (11.4%) 0 13.1% 
2016 Broiler meat at retail 309 15 (4.9%) 53 (17.1%)4 0 22.0% 
2018 Broiler meat at retail 300 9 (3.0%) 37 (12.3%) 0 15.3% 
1 based on phenotypic characterization, see appendix 3. 
2 CP-EC, carbapenemase-producing Escherichia coli 
3 one isolate was resistant also to cefoxitin 
4 phenotype of one isolate was confirmed only with AmpC & ESBL ID Set (D68C, Mast Diagnostics, UK) 
 
3.2 ESBL/AmpC- and carbapenemase-producing E. coli in imported poultry flocks 
 
In 2018, liners of transport boxes of 42, five and five imported poultry flocks intended for broiler meat, turkey 
meat and chicken egg production chains, respectively, were screened for ESBL/AmpC- and carbapenemase-
producing E. coli (Table 7). Positive flocks were not detected in any of the groups.  
 
Over the prior screening period of 2013-2017, none of the tested turkey flocks have been found to harbour 
ESBL/AmpC-producing E. coli whereas 11 to 75% and 0 to 75% of the imported broiler and chicken egg 
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production flocks, respectively, have been positive. Carbapenemase-producing E. coli have not been 
detected. This is the first year that all the tested imported poultry flocks appear to be free also from 
ESBL/AmpC-producing E. coli. 
 
Table 7. Results of the specific screening of ESBL- and AmpC-producing E. coli in liners from the transport boxes of 
imported poultry flocks and eggs. 
Imported poultry flocks  2013 2014 2015 2016 2017 2018 
   For broiler meat production 
Nr of sampled flocks 4 37 54 62 37 42 
Nr of ESBL positive flocks 2 1 1 0 0 0 
Nr of AmpC positive flocks 2 3 9 24 8 0 
Nr (%) of ESBL/AmpC positive floks 3 (75 %) 4 (11 %) 10 (19 %) 24 (39 %) 8 (22 %) 0 (0 %) 
   For turkey production 
Nr of sampled flocks 5 5 6 5 4 5 
Nr of ESBL positive flocks 0 0 0 0 0 0 
Nr of AmpC positive flocks 0 0 0 0 0 0 
Nr (%) of ESBL/AmpC positive floks 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %) 
   For egg production 
Nr of sampled flocks 3 6 4 3 4 5 
Nr of ESBL positive flocks 0 1 1 0 0 0 
Nr of AmpC positive flocks 1 3 2 0 3 0 
Nr (%) of ESBL/AmpC positive floks 1 (33 %) 4 (67 %) 3 (75 %) 0 (0 %) 3 (75 %) 0 (0 %) 
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4 Antimicrobial resistance in animal pathogens from food-producing 
animals 
 
 
 
 
Animal pathogens isolated from food-producing animals in this report include Escherichia coli from porcine 
enteritis, Staphylococcus aureus from broiler arthritis and tenosynovitis, E. coli from colibacillosis in broilers, 
bovine respiratory pathogens Pasteurella multocida, Mannheimia haemolytica and Histophilus somni, swine 
respiratory pathogen Actinobacillus pleuropneumoniae, and Brachyspira pilosicoli from pigs. CLSI clinical 
breakpoints are used when available. Details of sampling, isolation procedures and susceptibility testing are 
described in Appendix 3. 
4.1 Escherichia coli from pig enteritis 
 
Escherichia coli isolates from pig enteritis cases were obtained from faecal or postmortem samples submitted 
to Evira. All isolates were confirmed by PCR to be enterotoxigenic. Altogether, 88 E. coli isolates from 34 
farms were included. However, the results are not representative of the whole Finnish pig enteritis E. coli 
population due to the low number of isolates and the fact that at least part of the isolates are likely to 
originate from farms with diarrheal problems and higher than average antimicrobial usage. 
 
The MIC distributions and the resistance percentages using epidemiological cut-off values are given in Table 
8. As before, resistance was commonly detected against ampicillin, fluoroquinolones, tetracycline, 
streptomycin, sulfamethoxazole and trimethoprim. Resistance against 3rd generation cephalosporins was 
detected in five isolates from three farms, all phenotypically AmpC. No ESBL-producers were detected. 
Resistance to florfenicol and chloramphenicol was low. No resistance was detected against colistin or 
gentamicin in 2016, 2017 or 2018. 
 
 
Table 8. Distribution of MICs for Escherichia coli from porcine enteritis in 2018 (n=88). Resistance percentage (%R) is 
the proportion of resistant isolates calculated using epidemiological cut-off values. 
Substance %R 95% C.I. 
Distribution (%) of MICs (mg/L) 
0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048 
Ampicillin 35.2 26.1-45.6       20.5 38.6 4.5 1.1  6.8 1.1  27.3    
Cefotaxime 4.5 1.8-11.1   17.0 63.6 14.8 4.5             
Ceftazidime 5.7 2.5-12.6     62.5 31.8 5.7            
Chloramphenicol 9.1 4.7-16.9        13.6 64.8 9.1 3.4 4.5 4.5      
Ciprofloxacin 27.3 19.1-37.4 5.6 61.4 5.7 20.5 4.5   2.3           
Colistin 0.0 0.0-4.2      69.3 26.1 4.5           
Enrofloxacin 11.4 6.3-19.7   69.3 19.3 8.0 1.1   2.3          
Florfenicol 1.1 0.2-6.2         53.4 43.2 2.3 1.1       
Gentamicin 0.0 0.0-4.2      78.4 19.3 2.3           
Nalidixic acid 21.6 14.3-31.3        55.7 15.9 4.5 2.3 10.2 5.7 5.7     
Streptomycin 31.8 22.0-41.0         43.2 19.3 5.7 4.5 9.1 18.2     
Sulfamethoxazole 35.2 26.1-45.6          45.5 17.0 2.3     1.1 34.1 
Tetracycline 27.2 19.1-37.4       63.6 8.0 1.1   6.8 4.5 10.2 5.7    
Trimethoprim 29.5 21.3-39.8    22.7 29.5 11.4 4.5 2.3    29.5       
Trim/sulfa1 26.1 18.1-36.2      73.9    26.1         
Bold vertical lines indicate epidemiological cut-off values for resistance. Dotted vertical lines indicate clinical breakpoints for susceptibility (left dotted vertical line) and 
resistance (right dotted vertical line). Clinical breakpoints are given only if they are available and differ from the epidemiological cut-off values. Hatched fields denote 
range of dilutions tested for each substance. Values above the range denote MIC values greater than the highest concentration in the range. MICs equal to or lower than 
the lowest concentration tested are given as the lowest concentration.  
1 Concentration of trimethoprim given, tested with sulfamethoxazole in concentration ratio of 1:20 
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Between 2016 and 2018, no dramatic changes can be seen in resistance levels to the tested antimicrobials 
(Figures 9 and 10) using epidemiological cut-off values. As in previous years, multidrug resistance (resistance 
to ≥3 antimicrobial classes) was commonly detected. The proportions of multidrug resistant isolates and 
isolates fully susceptibility to the tested antimicrobials have been relatively similar during the last three years 
(Figure 9). 
 
Clinical resistance was also commonly detected to all antimicrobial classes that can be used to treat E. coli 
infections in pigs (sulfonamide-trimethoprim, tetracycline, aminopenicillins, fluoroquinolones). When the 
clinical breakpoints were applied, 36 isolates (41%) from 18 farms (52%) were multidrug resistant in 2018. 
Note that for fluoroquinolones (enrofloxacin), interpretation of resistance using clinical breakpoints differs 
the most compared to the epidemiological cut-off values (Table 8). 
 
Figure 9. The proportions of multidrug resistant E. coli isolates from porcine enteritis in years 2016-2018 using 
epidemiological cut-off values. Numbers of isolates tested each year in brackets. 
 
 
 
Figure 10. Proportion of resistance to the tested antimicrobials in Escherichia coli from porcine enteritis between 2016 
and 2018 using epidemiological cut-off values. Number of isolates tested each year in brackets. 
AMP, ampicillin; STR, streptomycin, TCY, tetracycline; SXT, trimethoprim-sulfamethoxazole; TRI, trimethoprim, SU, sulfamethoxazole; NAL, nalidixic acid; CIP, 
ciprofloxacin; ENR; enrofloxacin; CHL, chloramphenicol; FOT, cefotaxime; CAZ, ceftazidime; FF, florfenicol 
 
4.2 Actinobacillus pleuropneumoniae from swine respiratory disease 
 
A. pleuropneumoniae is the most important respiratory pathogen in growing pigs in Finland. In 2018, 
altogether 32 isolates from 25 farms were tested for antimicrobial susceptibility. All obtained isolates were 
included. As in previous years, intermediate susceptibility against oxytetracycline was common (Table 9). No 
resistance against tiamulin, tulathromycin, florfenicol or ceftiofur was detected. Between 2016 and 2018, no 
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significant changes in the MICs for the tested substances can be seen. However, the number of tested isolates 
each year is rather small.  
 
Table 9. Distribution of MICs for Actinobacillus pleuropneumoniae from pigs in 2018 (n=32). 
Substance %R 95% C.I. 
Distribution (%) of MICs (mg/L) 
≤0.12 0.25 0.5 1 2 4 8 16 32 64 >64 
Florfenicol 0.0 0.0-10.7  96.9 3.1         
Ceftiofur 0.0 0.0-10.7  100          
Penicillin1 0.0 0.0-10.7 40.6 37.5 21.9         
Oxytetracycline 0.0 0.0-10.7   84.4 15.6        
Tiamulin 0.0 0.0-10.7    3.1   46.9 50.0    
Tulathromycin 0.0 0.0-10.7      3.1 9.4 40.6 46.9   
Bold vertical lines indicate clinical breakpoints for susceptibility (left vertical line) and resistance (right vertical line). Hatched fields denote range of dilutions tested for 
each substance. Values above the range denote MIC values greater than the highest concentration in the range. MICs equal to or lower than the lowest concentration 
tested are given as the lowest concentration. 
1 clinical breakpoint not available 
 
4.3 Brachyspira pilosicoli from pigs 
 
There are no standardised breakpoints established for Brachyspira pilosicoli from pigs. As a guide for the 
choice of antimicrobial for treatment of spirochaetal diarrhoea, a clinical breakpoint for tiamulin of >1 mg/L, 
for tylosin of >2 mg/L, for valnemulin of >1 mg/L and for lincomycin of >4 mg/L are used in Finland. With 
these breakpoints, 65% of the isolates were resistant to tylosin and 15% to lincomycin (Table 10). No 
resistance against tiamulin and valnemulin was detected. Resistance in B. pilosicoli has been at the same level 
2015-2018, although the number of isolates tested each year are too small to draw any definite conclusions. 
 
 
Table 10. Distribution of MICs for Brachyspira pilosicoli from pigs in 2018 (n=20). 
Substance 
Distribution (%) of MICs (mg/L) 
≤0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 >128 
Doxycycline   25.0 55.0  5.0 15.0        
Lincomycin     70.0 10.0 5.0   10.0 5.0    
Tiamulin  70.0 15.0 10.0 5.0          
Tylosin       35.0 40.0 10.0    5.0 10.0 
Tylvalosin     25.0 30.0 25.0 10.0   5.0 5.0   
Valnemulin 70.0 5.0 20.0 5.0           
No clinical breakpoints available. Hatched fields denote range of dilutions tested for each substance. Values above the range denote MIC values greater than the highest 
concentration in the range. MICs equal to or lower than the lowest concentration tested are given as the lowest concentration. 
 
 
4.4 Histophilus somni, Pasteurella multocida and Mannheimia haemolytica from 
bovine respiratory disease 
 
During 2018, the number of farms sending samples for respiratory disease diagnostics dropped compared to 
the two previous years. One isolate per submission (and from each compartment if more than one was 
sampled) and per bacterial species was selected for susceptibility testing. H. somni isolates were obtained 
from 28 farms and 93% (26/28) of these had only isolates fully susceptible to the tested antimicrobials. 
H. somni isolates resistant or intermediate to oxytetracycline was detected and originated from two farms. 
 
Pasteurella multocida isolates were obtained from 124 farms and 96% (199/124) of them had fully 
susceptible isolates. Decreased susceptibility to oxytetracycline was the most common resistance trait 
although detected at low level. Mannheimia haemolytica isolates were obtained from 44 farms and 81% 
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(39/44) of them had fully susceptible isolates. The proportion of M. haemolytica isolates resistant 
oxytetracycline continued to increase, as well as the proportion of isolates with decreased sensitivity to 
penicillin.  
 
 
Table 11. Distribution of MICs for Histophilus somni from bovine respiratory disease in 2018 (n=30). 
Substance %R 95% C.I. 
Distribution (%) of MICs (mg/L) 
≤0.12 0.25 0.5 1 2 4 8 16 32 64 >64 
Ceftiofur 0.0 0.0-11.4  100          
Enrofloxacin 0.0 
0.0 
0.0-11.4 100           
Florfenicol 0.0 0.0-11.4  100          
Oxytetracycline 3.3 0.6-16.7   90.0  3.3 3.3  3.3    
Penicillin 0.0 0.0-11.4 90.0 10.0          
Tulathromycin 0.0 0.0-11.4    10.0 30.0 40.0 20.0     
Bold vertical lines indicate clinical breakpoints for susceptibility (left vertical line) and resistance (right vertical line). Hatched fields denote range of dilutions tested for 
each substance. Values above the range denote MIC values greater than the highest concentration in the range. MICs equal to or lower than the lowest concentration 
tested are given as the lowest concentration. 
 
 
Table 12. Distribution of MICs for Pasteurella multocida from bovine respiratory disease in 2018 (n=186). 
Substance %R 95% C.I. 
Distribution (%) of MICs (mg/L) 
≤0.12 0.25 0.5 1 2 4 8 16 32 64 >64 
Ceftiofur 0.0 0.0-2.0  98.9 1.1         
Enrofloxacin 0.0 0.0-2.0 99.5  0.5         
Florfenicol 0.0 0.0-2.0  74.2 25.3 0.5        
Oxytetracycline 3.2 1.5-6.9   78.5 8.6 9.1 0.5  3.2    
Penicillin 0.0 0.0-2.0 98.4 1.1 0.5         
Tulathromycin 0.5 0.1-3.0    39.2 41.9 16.7  1.6   0.5 
Bold vertical lines indicate clinical breakpoints for susceptibility (left vertical line) and resistance (right vertical line). Hatched fields denote range of dilutions tested for 
each substance. Values above the range denote MIC values greater than the highest concentration in the range. MICs equal to or lower than the lowest concentration 
tested are given as the lowest concentration. 
 
 
Table 13. Distribution of MICs for Mannheimia haemolytica from bovine respiratory disease in 2018 (n=49). 
Substance %R 95% C.I. 
Distribution (%) of MICs (mg/L) 
≤0.12 0.25 0.5 1 2 4 8 16 32 64 >64 
Ceftiofur 0.0 0.0-7.4  97.9 2.1         
Enrofloxacin 0.0 0.0-7.4 97.9 2.1          
Florfenicol 0.0 0.0-7.4   81.3 18.7        
Oxytetracycline 4.2 1.2-14.0   95.8     4.2    
Penicillin 12.5 5.9-24.7 45.8 25 16.7 8.3    4.2    
Tulathromycin 0.0 0.0-7.4     14.6 85.4      
Bold vertical lines indicate clinical breakpoints for susceptibility (left vertical line) and resistance (right vertical line). Hatched fields denote range of dilutions tested for 
each substance. Values above the range denote MIC values greater than the highest concentration in the range. MICs equal to or lower than the lowest concentration 
tested are given as the lowest concentration. 
 
4.5 Escherichia coli from colibacillosis and other infections in broilers 
 
Since 2014, colibasillosis has been a major problem in broiler production in Nordic countries including 
Finland. In 2017, a vaccination program with an autogen vaccine against two major serotypes was started in 
some broiler chains and the colibacillosis situation appears to be slightly better in 2018. Colibacillosis 
infections in broilers or broiler parents are not treated with antimicrobials in Finland. Most of the samples 
are obtained from parent flocks. Based on epidemiological cut-off values, resistance was less common in 
2018 than in previous years and was detected only against tetracycline and trimethoprim (Table 14). Only 
single isolates resistant to 3rd generation cephalosporins were found in 2016 and 2017 (FINRES-Vet 2016-
2017) but not at all in 2018. The occurence of resistance to different antimicrobials has varied annually which 
is probably due to the small number of tested isolates.   
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Table 14. Distribution of MICs for Escherichia coli from colibacillosis in 2018 (n=19) 
Substance %R 95% C.I. 
Distribution (%) of MICs (mg/L) 
0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048 
Ampicillin 0.0 0.0-16.8       15.8 68.4 10.5 5.3         
Cefotaxime1 0.0 0.0-16.8   29.4 70.6               
Ceftazidime1 0.0 0.0-16.8     82.4 17.6             
Ciprofloxacin 0.0 0.0-16.8  89.5 10.5                
Colistin1 0.0 0.0-16.8      82.4 17.6            
Sulfamethoxazole 0.0 0.0-16.8          84.2 10.5 5.3       
Tetracycline 10.6 2.9-31.4       63.2 26.3    5.3 5.3      
Trimethoprim 5.3 0.9-24.6     47.4 42.1  5.3    5.3       
Bold vertical lines indicate epidemiological cut-off values for resistance. Hatched fields denote range of dilutions tested for each substance. Values above the range 
denote MIC values greater than the highest concentration in the range. MICs equal to or lower than the lowest concentration tested are given as the lowest 
concentration.  
1 n=17 
 
 
4.6 Staphylococcus aureus from tenosynovitis in broilers 
 
Staphylococcus aureus from broiler tenosynovitis cases were isolated from clinical and post-mortem samples 
submitted to Evira. All obtained S. aureus isolates were included. Twenty-one isolates from 13 farms were 
studied. All isolates were susceptible to the reported antimicrobials (Table 15). No isolates were found to 
produce beta-lactamase and no MRSA isolates were found. Tenosynovitis is occasionally treated with 
antimicrobials in broiler parent flocks but annually only a small number of flocks are treated. Production 
flocks have not been treated with antimicrobials since 2010 (Animal Health ETT ry. https://www.ett.fi/wp-
content/uploads/2019/09/Use-of-antibiotics-in-poultry-meat-production-in-Finland-2007-2018.pdf).  
 
Table 15. Distribution of MICs for Staphylococcus aureus from tenosynovitis in broilers in 2018 (n=21). 
Substance %R 95%C.I. 
Distribution (%) of MICs (mg/L) 
0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 
Cefoxitin 0.0 0.0-15.5       14.3 85.7     
Penicillin1 0.0
 
0.0-
15.5 
0.0-15.5 81.0 14.3 4.8          
Tetracycline 0.0 0.0-15.5     100        
Trim/sulfa2 0.0 0.0-15.5   100          
Bold vertical lines indicate epidemiological cut-off values for resistance. Hatched fields denote range of dilutions tested for each substance. Values above the range denote MIC 
values greater than the highest concentration in the range. MICs equal to or lower than the lowest concentration tested are given as the lowest concentration. 
1 resistance profiles based on beta-lactamase production 
2 concentration of trimethoprim given, tested with sulfamethoxazole in concentration ratio of 1:20 
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5 Antimicrobial resistance in animal pathogens from companion 
animals and horses 
 
 
 
 
Antimicrobial resistance figures from companion animal pathogens (dogs, cats and horses) were collected 
from the Clinical Microbiology Laboratory of the Faculty of Veterinary Medicine, University of Helsinki. In this 
context antimicrobial resistance corresponds to the proportion of resistant and intermediate isolates. The 
reporting period covers January 2014 – December 2018 and includes solely bacterial isolates derived from 
clinical infections. Approximately 36% of specimens were from the Veterinary Teaching Hospital of the 
University of Helsinki and 64% from private veterinary clinics. If the number of tested bacterial isolates for 
the bacterial species in question was large enough, data are presented separately for dogs, cats and horses. 
Otherwise, collated data are presented. Details of the susceptibility testing method are described in Appendix 
3. 
 
5.1 Staphylococcus aureus from companion animals and horses 
 
The material included 331 S. aureus isolates (42 – 107 isolates per year) from dogs, cats and horses. 
Antimicrobial resistance in this pathogen was low to very low (Figure 11), except for penicillin. Beta-
lactamase results were available for 271 isolates (2014-2018), of which 67% were positive. Beta-lactamase 
production was more common in canine S. aureus isolates (79%, 136/172) than in equine isolates (19%, 8/43) 
(p<0.0001, Chi-square test), while there was no statistical difference in beta-lactamase production between 
canine and feline (68%, 38/56) S. aureus isolates (p=0.86, Chi-square test). 
 
Oxacillin resistance (indicating the presence of MRSA) was generally at a low level, ranging from 0 – 9%, being 
6.3% in 2018. Of the six MRSA isolates detected in 2018, five were from specimens submitted by different 
private clinics. Four isolates were from dogs and two others from a cat and a horse. 
 
 
 
Figure 11. Antimicrobial non-susceptibility (%) in Staphylococcus aureus from dogs, cats and horses in 2014-2018. The 
number of tested isolates per year: 44 (2014), 42 (2015), 42 (2016), 107 (2017) and 96 (2018). 
OXA, oxacillin; ERY, erythromycin; CLI, clindamycin; SXT, trimethoprim-sulfamethoxazole; TCY, tetracycline; FUS, fucidic acid. 
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5.2 Staphylococcus pseudintermedius from dogs 
 
Antimicrobial resistance remained at a relatively high level in Staphylococcus pseudintermedius for 
erythromycin and clindamycin in 2018, despite the slightly decreasing tendency during the previous years. 
Decreasing resistance levels for tetracycline (as well as for doxycycline) and fucidic acid were noted during 
the whole period. Sulfonamide-trimethoprim resistance remained stable – around 10-12% – during the whole 
period (Figure 12). 
 
The proportion of MRSP isolates, as indicated by oxacillin non-susceptibility, was moderate (12-14%) in 2014-
2016, but then decreased to 9% in 2017, and further down to 6% in 2018 (Figure 12). Chloramphenicol 
resistance remained stable, between 14 and 19%, during the whole period, but non-susceptibility to 
enrofloxacin decreased (from 7% to 3% during the whole period) (Figure 13). 
 
 
 
Figure 12. Antimicrobial non-susceptibility (%) in canine Staphylococcus pseudintermedius isolates in Finland in 2014-
2018 for primary antimicrobial agents. Number of tested isolates per year: 401 (2014), 396 (2015), 477 (2016), 749 
(2017), 936 (2018). For each antimicrobial, there can be small variations from these numbers. 
OXA, oxacillin; ERY, erythromycin; CLI, clindamycin; SXT, trimethoprim-sulfamethoxazole; TCY, tetracycline; FUS, fucidic acid 
 
 
 
Figure 13. Antimicrobial non-susceptibility (%) in canine Staphylococcus pseudintermedius isolates in Finland in 2015-
2018 for secondary antimicrobial agents. Number of tested isolates per year: 396 (2015), 477 (2016), 749 (2017), 936 
(2018). For each antimicrobial, there can be some variations from these numbers. 
DOX, doxycycline; GEN, gentamicin; AMK, amikacin; ENR, enrofloxacin; CHL, chloramphenicol  
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5.3 Escherichia coli from dogs and cats 
 
Altogether, 1837 canine and 334 feline Escherichia coli isolates were tested during the years 2014-2017, but 
in 2018 alone there where 1041 canine and 187 feline isolates (in total 2878 canine and 521 feline isolates in 
2014-2018). Resistance figures for canine and feline E. coli are presented in Figure 14 and 15, respectively. In 
general, feline E. coli isolates were more susceptible to antimicrobials than canine isolates, although they 
were more resistant in 2018 than in the previous years.  
 
Ampicillin non-susceptibility was similar in both canine and feline E. coli isolates in 2018 (37% vs. 35%, 
respectively). However, in canine isolates, the proportion of ampicillin non-susceptible strains was 
significantly lower (p<0.00001, Chi-square test) in 2018 (37%) than in 2017 (50%). Feline E. coli isolates had 
a greater proportion of resistance to ampicillin in 2018 when compared to 2017 (35% vs. 27%), but the 
difference was not statistically significant (p=0.08, Chi-square test). In canine E. coli, the resistance to 
amoxicillin-clavulanic acid continued to decrease. In 2018, the proportion of non-susceptible strains was 11%, 
when in 2017 the corresponding figure was 16%.  
 
Enrofloxacin resistance in canine E. coli isolates decreased during the last four years, being less than 7% in 
2018. Sulfonamide-trimethoprim resistance in canine and feline E. coli fluctuated through the monitoring 
period, having been 13% in dogs and 7% in cats in 2018.  
 
In 2018, 5.3% of canine E. coli were resistant to cefpodoxime indicating reduced susceptibility to third 
generation cephalosporins, with a downward drift from 2016 to 2018 (Figure 16). The proportion of ESBL-
producing isolates continued to decrease, being 1.2% in 2018, but the proportion of AmpC-producing isolates 
remained quite stable compared to 2017 (3.7% in 2018). Less than 3% of feline E. coli isolates had either ESBL 
or AmpC phenotype.   
 
 
 
Figure 14. Antimicrobial non-susceptibility (%) in canine E. coli in Finland in 2014-2018. Number of tested isolates: 310 
(2014), 390 (2015), 457 (2016), 680 (2017), 1041 (2018). 
AMP, ampicillin; AMC, amoxicillin-clavulanic acid; CPD, cefpodoxime; SXT, trimethoprim-sulfamethoxazole; GEN, gentamicin; ENR, enrofloxacin 
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Figure 15. Antimicrobial non-susceptibility (%) in feline E. coli in Finland in 2014-2018. Number of tested isolates: 58 
(2014), 50 (2015), 75 (2016), 151 (2017), 187 (2018). 
AMP, ampicillin; AMC, amoxicillin-clavulanic acid; CPD, cefpodoxime; SXT, trimethoprim-sulfamethoxazole; GEN, gentamicin; ENR, enrofloxacin 
 
 
 
Figure 16. Proportion of isolates with reduced susceptibility to cefpodoxime (CPD), and proportion of ESBL and AmpC 
positive isolates in canine E. coli, 2014-2018. 
CPD, cefpodoxime 
 
 
5.4 Streptococci from dogs and horses 
 
All Streptococcus canis isolates from dogs were susceptible to penicillin and nearly all to sulfamethoxazole-
trimethoprim (Figure 17). Erythromycin and clindamycin resistance rates remained stable: in 2018, 8% and 
11% of isolates showed resistance to these antimicrobials, respectively. Tetracycline resistance was at a high 
level although a decreasing tendency was observed. 
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Figure 17. Antimicrobial resistance (%) in canine S. canis isolates in Finland in 2014-2018. Number of tested strains: 
135 (2014), 157 (2015), 207 (2016), 293 (2017), 392 (2018). 
PEN, penicillin; ERY, erythromycin, CLI, clindamycin, SXT, trimethoprim-sulfamethoxazole, TCY, tetracycline 
 
 
During the period of 2014-2018, 174 Streptococcus equi ssp. zooepidemicus isolates were tested. All of the 
isolates were susceptible to penicillin. For sulfamethoxazole-trimethoprim, the increasing trend in the 
proportion of resistant strains did not continue after 2017: in 2018, 7% (3/47) of the strains expressed 
resistance, while the corresponding proportion in 2017 was 12% (4/47). The development of this resistance 
still has to be monitored carefully due to the importance of this drug in the treatment of many equine 
infections. 
 
5.5 Pseudomonas aeruginosa from dogs 
 
In 2018, 105 isolates of canine Pseudomonas aeruginosa were tested. Overall, the strains were quite 
susceptible to all tested antimicrobials. Three percent of the strains expressed amikacin resistance, and 4% 
were non-susceptible to gentamicin. No resistance to polymyxin B or tobramycin was detected. Most isolates 
(88%) were susceptible to ciprofloxacin. As expected, the opposite was true for enrofloxacin because majority 
of the isolates (64%) showed intermediate susceptibility for this antimicrobial even though they were 
susceptible to ciprofloxacin. Approximately 18% of the isolates were resistant to enrofloxacin. However, since 
enrofloxacin is metabolized to ciprofloxacin in-vivo, resistance testing with current breakpoints may 
overestimate the non-susceptibility, especially because in many cases infections caused by P. aeruginosa are 
treated with locally administered antimicrobials. 
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6 Antimicrobial resistance in indicator bacteria from food-producing 
animals 
 
 
 
 
Resistance in the commensal gram-negative indicator E. coli is a reflection of the most common resistance 
traits among the gram-negative bacteria present in the gut microbiota, the selection pressure caused by the 
antimicrobials used in the animal population. In this report, resistance of the indicator E. coli from 
slaughtered broilers are presented. Details of the sampling and laboratory analysis are described in Appendix 
3. 
 
6.1 Indicator E. coli from broilers 
 
In 2018, a total of 173 isolates from broilers were tested for antimicrobial susceptibility to 14 antimicrobials.  
The majority of the isolates was fully susceptible to the tested antimicrobial classes. The most common 
resistance traits detected were against ampicillin (13%), tetracycline (6%), ciprofloxacin (6%) 
sulfamethoxazole (6%) and trimethoprim (5%) (Table 18). The number of resistant isolates against 
tetracycline continued to decrease while the proportion of resistant isolates against the other 
aforementioned antimicrobials increased from the year 2016 (Figure 16).  
 
Further, 5% of the isolates were multiresistant and their proportion has almost doubled from 2014 (Figure 
17, data from the years prior to 2014 are not included as they are not completely comparable because partly 
different antimicrobials were included in the susceptibility testing). The most commonly detected resistance 
profiles in the multiresistant isolates in 2018 were resistance against ampicillin, sulfamethoxazole, 
ciprofloxacin and nalidixic acid, and against ampicillin, tetracycline, sulfamethoxazole and trimethoprim 
(Table 19). Also, as in 2016, one AmpC isolate was detected. 
 
Table 18. Distribution of MICs for indicator Escherichia coli in broilers in 2018 (n=173). 
Substance %R 95% C.I. 
Distribution (%) of MICs (mg/L) 
0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048 
Ampicillin 13.3 9.0-19.2       0.6 30.6 52.6 2.9    13.3     
Azithromycin ND -        2.3 66.5 30.6 0.6        
Cefotaxime 0.6 0.1-3.2     99.4     0.6         
Ceftazidime 0.6 0.1-3.2      99.4     0.6        
Chloramphenicol 0.6 0.1-3.2          97.1 2.3   0.6     
Ciprofloxacin 5.8 3.2-10.3 81.5 12.7  0.6 3.5 0.6    1.2         
Colistin 0 0.0-2.2       100            
Gentamicin 1.2 0.3-4.1      32.4 60.1 6.4    1.2       
Meropenem 0 0.0-2.2  100                 
Nalidixic acid 5.8 3.2-10.3         93.1 1.2   0.6 2.3 2.9    
Sulfamethoxazole 6.4 3.6-11.0          75.1 17.9 0.6      6.4 
Tetracycline 6.4 3.6-11.0        85.5 7.5 0.6  0.6 1.7 4.0     
Tigecycline 0 0.0-2.2     93.1 6.9             
Trimethoprim 5.2 2.8-9.6     56.1 36.4 1.7 0.6     5.2      
Bold vertical lines indicate epidemiological cut-off values for resistance. Hatched fields denote range of dilutions tested for each substance. Values above the range denote 
MIC values greater than the highest concentration in the range. MICs equal to or lower than the lowest concentration tested are given as the lowest concentration. ND, 
not determined 
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Figure 16. Resistance in indicator E. coli from broilers to selected antimicrobials in 2002-2018. In brackets the number 
of isolates tested each year. 
 
 
 
Figure 17. Antimicrobial susceptibility of indicator E. coli from broilers at slaughter in Finland between the years 2014 
and 2018. Numbers of the isolates tested each year are the same as in Figure 16. 
 
 
Table 19. Detected resistance profiles among indicator E. coli from broilers in 2014, 2016 and 2018. 
Resistance profile 
Nr of isolates in each year 
2014 2016 2018 
AMP-SU-TRI 0 0 1 
AMP-SU-CIP-NAL 0 1 3 
AMP-TET-SU-TRI 0 1 3 
AMP-TET-SU-TRI-CIP-NAL 0 0 1 
AMP-SU-TRI-CIP-NAL 0 1 0 
AMP-CAZ-CIP-FOT-NAL-SU-TET-TRI 0 1* 0 
TET-SU-TRI 5 3 0 
TET-SU-TRI-CIP-NAL-GEN-CHL 0 0 1 
AMP-CAZ-FOT 0 0 1* 
AMP-CIP 0 1 0 
AMP-CIP-NAL 2 0 1 
AMP-TET 5 3 4 
AMP-SU 1 0 1 
AMP-TRI 0 1 1 
CIP-NAL 5 2 4 
CIP-NAL-SU 0 1 0 
CIP-NAL-TRI 1 0 0 
GEN-SU 0 0 1 
SU-TRI 2 0 0 
SU-TET 4 2 0 
AMP 0 7 7 
GEN 1 0 0 
TET 5 8 2 
TRI 1 0 2 
Susceptible 143 152 140 
Abbreviations: AMP, Ampicillin; CAZ, ceftazidime; CHL, chloramphenicol; CIP, ciprofloxacin; FOT, cefotaxime; GEN, gentamicin; NAL, nalidixic acid; 
SU, sulfamethoxazole; TET, tetracycline; TRI, trimethoprim. 
Multiresistant phenotypes are bolded; *Phenotypically AmpC  
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Appendix 1. Population statistics 
 
 
The population of food-producing animals (as PCU) is presented in Table 20. The number of livestock and 
farms, and the production of meat and milk in Finland are presented in Tables 21-24 (Source: Luke, the 
Natural Resources Institute Finland). 
 
Table 20. Population of food-producing animals as PCU (1000 tonnes) in 2010-2018. 
 2010 2011 2012 2013 2014 2015 2016 2017 2018 
Cattle 227,06 226,64 224,27 224,33 226,22 228,97 228,06 221,73 219,91 
Pigs 182,22 181,63 171,19 169,61 162,55 162,98 161,26 152,79 141,57 
Poultry 59,51 61,82 65,30 66,91 68,32 70,25 73,32 76,37 81,62 
Sheep and goats 10,17 10,59 10,65 11,10 11,38 12,83 13,00 12,97 13,02 
Horses 29,72 30,20 30,16 30,00 29,84 29,68 29,68 29,76 29,76 
Fish 11,772 11,275 12,659 13,613 13,465 14,877 14,413 14,587 14,324 
 
 
Table 21. Number of livestock (in thousands) in Finland in 2010-2018. 
  2010 2011 2012 2013 2014 2015 2016 2017 2018 
Dairy cows 289 286 284 283 285 285 282 275 271 
Suckler cows 55 57 58 57 58 59 59 60 60 
Cattle > 1 year1 278 273 268 271 268 264 258 261 252 
Calves < 1 year 303 299 303 300 303 307 310 297 299 
TOTAL, Cattle 926 914 913 912 914 915 909 893 882 
Boars and sows 154 146 136 128 123 NA2 NA NA NA 
Pigs > 20 kg 804 797 779 815 760 NA NA NA NA 
Piglets < 20 kg 409 392 375 365 362 NA NA NA NA 
TOTAL, pigs 1367 1335 1290 1308 1245 1243 1235 1136 1089 
Laying hens 3394 3304 3173 3432 3645 3595 3599 3746 3985 
Chicks 838 745 743 858 714 662 748 509 608 
Broilers 4616 5421 6038 6861 7341 7827 8272 8047 8781 
Turkeys 280 308 295 274 292 246 260 292 299 
Other poultry2 459 457 512 555 584 597 566 543 468 
TOTAL, poultry 9587 10236 10761 11981 12577 12927 13445 13136 14140 
1 Heifers and bulls in total 
2 Including broilerhens 
Number of cattle on 1.5. Number of pigs and poultry 1.4. 
Number of poultry in 2016 not totally comparable with the previous years. 
Source:  OFS: Luke, Number of livestock. 
 
 
Table 22. Number of farms in Finland in 2010-2018. 
  2010 2011 2012 2013 2014 2015 2016 2017 2018 
Cattle farms total 15641 14919 14141 13416 12885 12389 11791 11175 10530 
Pig farms total 2078 1917 1747 1637 1486 1337 1240 1102 1027 
Poultry farms total 1304 1314 1155 1207 1299 1310 1300 1280 1243 
Source: OFS: Luke, Number of livestock, http://stat.luke.fi/en/number-of-livestock. 
 
 
Table 23. The production of meat and fish (million kg) in Finland in 2010-2018. 
  2010 2011 2012 2013 2014 2015 2016 2017 2018 
Beef1 82 83 80 80 82 86 86 85 86 
Pork1 203 202 193 194 186 192 190 182 169 
Poultry1 96 102 107 111 113 117 125 129 135 
Total 383 387 382 387 383 397 403 397 391 
                   
Fish2 12 11 13 14 13 15 14 15 14 
1 In slaughterhouses; 2 for human consumption, ungutted 
Source: OFS: Luke, Meat production, http://stat.luke.fi/en/meat-production and Aquaculture, http://stat.luke.fi/en/aquaculture. 
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Table 24. The production of milk in Finland in 2010-2018. 
  2010 2011 2012 2013 2014 2015 2016 2017 2018 
Milk production; per 
animal (litres) 
7896 7859 7876 7977 8201 8323 8406 8534 8650 
Total milk production 
(million litres) 
2268 2234 2230 2260 2330 2365 2359 2336 2328 
Source: OFS: Luke, Milk and milkproducts statistics, http://stat.luke.fi/en/milk-and-milk-product-statistics. 
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Appendix 2. Sales of antimicrobials for animals, kg active ingredient 
 
 
Table 25. Overall sales of veterinary antimicrobials in Finland 2010-2018, kg active ingredient. 
 2010 2011 2012 2013 2014 2015 2016 20171 2018 
Tetracyclines 1728 1838 1759 2389 2576 2250 2010 2268 2218 
Amphenicols 59 124 61 121 84 80 87 104 112 
Penicillin G 5162 5010 4784 4721 4502 4332 3773 4018 4055 
Aminopenicillins 1317 1284 1342 1314 1374 1498 1438 1160 1020 
Cloxacillin 114 112 97 82 91 65 63 45 39 
1st gen. cephalosporins 906 1056 902 793 753 605 513 355 284 
3rd gen. cephalosporins 5 9 15 8 8 7 3 1 0,5 
Sulfonamides and trimethoprim1 3274 3045 3149 3129 2893 2445 2460 2216 1682 
Macrolides 572 532 575 456 521 596 517 408 411 
Lincosamides 202 164 179 155 189 165 120 297 184 
Aminoglycosides 166 128 108 103 101 93 87 73 61 
Fluoroquinolones 96 102 107 105 113 94 99 80 81 
Pleuromutilins 48 73 66 43 44 30 23 14 10 
Total sales 13651 13475 13144 13419 13250 12262 11192 11037 10157 
1 Sales of sulfonamides and trimethoprim in 2017 corrected 
 
Table 26. Sales of injectable veterinary antimicrobials in Finland 2010-2018, kg active ingredient. 
 2010 2011 2012 2013 2014 2015 2016 2017 2018 
Tetracyclines 527 515 521 558 552 640 686 671 642 
Amphenicols 0 12 13 26 17 6 13 26 15 
Penicillin G 5023 4849 4552 4542 4243 4047 3450 3777 3804 
Aminopenicillins 440 404 434 379 416 473 453 338 286 
1st gen. cephalosporins 0 0 0 0 0 0 5 1 1 
3rd gen. cephalosporins 5 9 15 8 8 7 3 1 0 
Sulfonamides and trimethoprim  329 297 360 344 358 373 322 317 286 
Macrolides 13 13 11 12 12 15 19 13 10 
Lincosamides 40 30 27 24 26 26 25 19 18 
Aminoglycosides 19 18 20 12 15 13 14 12 10 
Fluoroquinolones 78 85 84 83 90 72 78 63 66 
Total sales of injectables 6472 6230 6036 5990 5737 5672 5069 5238 5139 
 
Table 27. Sales of orally administered veterinary antimicrobials (premixes, oral solutions, oral powders, oral pastes and 
tablets) in Finland 2010-2018, kg active ingredient 
 2010 2011 2012 2013 2014 2015 2016 20171 2018 
Tetracyclines  1202 1323 1237 1830 2024 1610 1324 1597 1575 
Amphenicols 59 112 48 95 67 74 74 78 97 
Penicillin G 0 17 110 47 122 147 190 100 105 
Aminopenicillins 856 860 893 923 947 1017 976 813 728 
1st gen. cephalosporins 872 1025 871 766 730 587 493 341 274 
Sulfonamides and trimethoprim1 2945 2747 2789 2784 2535 2072 2138 1899 1397 
Macrolides 559 519 565 444 510 581 498 395 402 
Lincosamides 161 134 152 130 164 139 94 278 165 
Aminoglycosides 95 79 76 76 70 62 54 41 32 
Fluoroquinolones 19 17 23 22 22 22 22 16 15 
Pleuromutilines 48 73 66 43 44 30 23 14 10 
Total sales of orally adm. 
products 
6816 6906 6829 7160 7236 6342 5885 5571 4798 
1 Sales of sulfonamides and trimethoprim in 2017 corrected 
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Tables 28A and 28B. Sales of intrammaries for veterinary use in Finland 2010-2018, kg active ingredient 
28A. Intramammaries for lactation phase 
 2010 2011 2012 2013 2014 2015 2016 2017 2018 
Penicillin1 104 107 94 94 100 94 85 92 98 
Aminopenicillins 15 14 11 8 8 7 7 6 5 
Cephalexin 29 30 31 27 22 18 15 13 9 
Cloxacillin 60 56 47 39 41 31 29 19 18 
Aminoglycosides 29 12 1 0 0 0 0 0 0 
Macrolides 1 1 0 0 0 0 0 0 0 
Total sales imm. lactation 
phase 
237 220 185 168 170 150 136 129 129 
1Sales of penicillin in 2013 corrected 
28B. Intramammaries for dry cow treatment 
 2010 2011 2012 2013 2014 2015 2016 2017 2018 
Penicillin1 35 38 28 38 37 44 47 50 48 
Aminopenicillins 6 6 5 4 3 2 2 3 1 
Cephalexin 6 1 0 0 0 0 0 0 0 
Cloxacillin 55 55 49 43 50 35 34 26 21 
Aminoglycosides 24 20 12 16 15 18 19 20 20 
Total sales imm. dry cow 126 120 94 101 106 98 102 100 90 
1Sales of penicillin in 2013 corrected 
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Appendix 3. Materials and methods, resistance monitoring 
 
 
Sampling strategy  
 
Zoonotic bacteria 
 
Salmonella isolates from food-producing animals were collected as required by the Finnish salmonella control 
programme. One isolate from each notified incident was included. Isolates from domestic food included also 
isolates originating from in-house control system. 
 
Campylobacter jejuni were collected from broilers in association with the Finnish Campylobacter control 
programme for broilers. Between 1st of June and 31st of October, every slaughtered broiler production batch 
was sampled and between 1st of November and 31st of May, the frequency is set annually depending on 
production volume. All isolates (one isolate per slaughter batch) are included in the antimicrobial 
susceptibility testing. 
 
Campylobacter spp. from fur animals were isolated from intestinal or faecal samples as part of diarrhea 
examination. 
 
Animal pathogens 
 
Clinical isolates originated from diagnostic submissions or postmortem examinations done in the former Evira 
laboratories. Escherichia coli was isolated from pigs with enteritis, the samples were taken from the contents 
of the gastrointestinal tract. All isolates examined were confirmed to be enterotoxigenic using PCR for toxin 
and fimbrial genes. Staphylococcus aureus from broiler tenosynovitis cases were isolated from post-mortem 
samples submitted to Evira. All obtained S. aureus isolates were included from the study period. A. 
pleuropneumoniae isolates originate from post mortem investigations of lungs most likely from pigs with 
respiratory disease. Bovine respiratory pathogens were mostly from deep nasopharyngeal swabs from non-
medicated calves suffering from acute respiratory disease. Also isolates from post mortem investigations of 
cattle lungs were included. E. coli isolates from broilers are from post mortem samples from parent or 
production pedigree, and isolated either from bone marrow or heart. Brachyspira pilosicoli isolates are from 
faecal samples of swine with diarrhea. 
 
Antimicrobial resistance figures from companion animal pathogens were collected from the clinical 
microbiology laboratory of the Faculty of Veterinary Medicine, University of Helsinki.  All isolates included in 
this report originated from clinical specimens. The data were available for the period of 2014-2018.  
 
Indicator bacteria and ESBL/AmpC/carbapenemase-producing E. coli in food-producing animals 
 
Indicator E. coli was isolated from broiler caeca in 2018. From the same samples, the screening of ESBL/AmpC 
and carbapenemase producing E. coli was done. The samples from broilers (n=289) originated from healthy 
animals at slaughter between January and December. The sampling was evenly distributed throughout the 
year. The number of randomly taken samples from each slaughterhouse was proportional to the annual 
slaughter volume. The broiler slaughterhouses accounted approximately for >99% of the total number of 
slaughtered animals in Finland. 
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From each flock, sample was taken from one bird. The samples were taken aseptically and transported 
refrigerated to the laboratory within two days. Samples taken on Fridays (from one slaughterhouse) were 
kept refrigerated from Friday to Monday and transported to the laboratory during the following Monday.  
 
Indicator E. coli isolates tested for susceptibility were randomly selected from all isolates available at the 
laboratory. Each isolate represented a different epidemiological unit (a flock). 
 
ESBL/AmpC/carbapenemase-producing E. coli in meat 
 
Randomly selected samples of packed fresh and chilled (not frozen) meat from broilers (n=300) were 
collected at retail between January and December in 2018. Sampling was evenly distributed throughout the 
year and allocated according to meat batches. Samples were collected from retail shops in six different NUTS-
3 areas, covering approximately 55% of the Finnish population. The meat samples were sliced or diced and 
wrapped in vacuum or in a controlled atmosphere. Broiler meat samples were all of domestic origin. 
 
The samples were transported refrigerated to the laboratory within 1 day. The temperature of the meat was 
measured at the laboratory at arrival. From the biggest NUTS-3 area, samples were also collected on Fridays 
and transported to the laboratory during the same day. One isolate from each epidemiological unit (if 
available) was selected for susceptibility testing. 
 
ESBL/AmpC/carbapenemase-producing E. coli in imported poultry flocks 
 
Imported flocks intended for broiler meat, turkey meat and egg production are screened for ESBL/AmpC- and 
carbapenemase-producing E. coli according to recommendations given by Animal Health ETT.  
 
Isolation and identification of bacteria 
 
Zoonotic bacteria 
 
Salmonella spp. were isolated and identified according to a modification of the NMKL standard Nr 71 (1999), 
according to ISO standard 6579:2002 or ISO standard 6579:2002, Amendment 1/2007, at local food control 
or slaughterhouse laboratories. Serotyping of the isolates was performed at Evira, Veterinary Bacteriology 
Unit. 
 
C. jejuni from broilers were isolated at slaughterhouse laboratories and confirmed at the former Evira, Food 
and Feed Microbiology Research Unit, according to a modified method of the NMKL 119:2007. 
 
Isolation and identification of C. jejuni from fur animals was performed by accredited conventional culture 
and biochemical/MALDI-TOF methods in Evira in Veterinary Bacteriology and Pathology Unit.  
 
Animal pathogens  
 
Isolation and identification of pathogens from food-producing animals was performed by accredited 
conventional culture and biochemical/MALDI-TOF methods in the former Finnish Food Safety Authority, 
Veterinary Bacteriology and Pathology Unit.  
 
Identification of pathogens from companion animals was performed by conventional biochemical methods 
(2014-2015) and since then by MALDI-TOF method in the clinical microbiology laboratory of the Faculty of 
Veterinary Medicine, University of Helsinki. Pathogens were from various types of specimens, such as 
superficial and deep pus specimens, urine, respiratory tract, and blood.     
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Indicator E. coli 
 
Intestinal content was directly spread on Brilliance™ E. coli/coliform Selective Agar (Oxoid) and incubated 
overnight at 37°C. Typical, purple colonies were subsequently spread on blood agar plates and after an 
overnight incubation at 37°C, stored at -80°C until susceptibility testing. 
 
Screening of ESBL-, AmpC- and carbapenemase-producing E. coli  
 
The screenings of ESBL/AmpC- and carbapenemase-producing E. coli from broilers and broiler meat samples 
were part of the EU-wide monitoring based on Comission Decision 2013/652/EU. The EURL protocols (www. 
https://www.eurl-ar.eu/protocols.aspx) were used for caecal samples from broilers (n=289) and the broiler 
meat samples (n=300). 
 
Briefly, 1 g of intestinal content or 25 g of fresh meat was suspended in 10 ml or 225 ml of buffered peptone 
water (BPW) (Merck, Germany), respectively, and incubated overnight at 37°C. Subsequently, 10 µl of the 
suspension was spread on MacConkey agar plates (Becton, Dickinson & Company, France) containing 1 mg/l 
cefotaxime (Sigma-Aldrich, Germany) for the detection of ESBL/AmpC producers, and on CARBA and OXA-48 
plates (Biomerieux) for the detection of carbapenemase producers. MacConkey plates were incubated 
overnight at 44°C, and CARBA and OXA-48 plates overnight at 37°C. Presumptive E. coli colonies from the 
selective plates were confirmed with MALDI-TOF (Maldi Biotyper®, Bruker Daltonics, Germany). 
 
The screening of ESBL/AmpC- and carbapenemase-producing E. coli from imported poultry flocks was 
conducted using the liners of transport boxes. As a general rule, ten liners from each import batch, were 
analysed as two pooled samples of five liners. Samples were analysed with the same method as ceacal and 
meat samples, suspending five liners in 3 liters of BPW. 
 
 
Susceptibility testing 
 
Verbal descriptions of the resistance levels are those used by EFSA (EFSA, 2010). 
 Rare  < 0.1% 
 Very low  0.1% to 1.0% 
 Low  >1% to 10% 
 Moderate  >10% to 20% 
 High  >20% to 50% 
 Very high  >50% to 70% 
 Extremely high >70% 
 
Bacteria from food-producing animals 
 
The susceptibility testing of bacteria from food-producing animals was performed with broth microdilution 
method according to the Clinical and Laboratory Standards Institute (CLSI) standard VET01-A4. The 
susceptibility testing of animal pathogens isolated was performed with a broth microdilution method using 
VetMICTM (Department of Antibiotics, National Veterinary Institute, Uppsala, Sweden) microtiter plates 
except for the bovine and porcine respiratory pathogens that were tested using SensititreTM (TREK Diagnostic 
Systems Ltd, United Kingdom) BOPO6F plates. The susceptibility of salmonella and indicator E. coli was 
performed using SensititreTM plates. The susceptibility of campylobacter was performed using VetMICTM 
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plates. The confirmation of presumptive ESBL/AmpC-producing bacteria was done by the AmpC & ESBL ID 
Set (D68C, Mast Diagnostics, UK) (pathogenic E. coli from food-producing animals) or by the microdilution 
method using SensititreTM EUVSEC2 plates (salmonella, indicator E. coli, isolates from the ESBL/AmpC 
screening). Beta-lactamase activity in S. aureus was tested with CefinaseTM disks (Becton Dickinson, NJ, USA). 
 
Susceptibility testing was performed at the former Evira, Food and Feed Microbiology Research Unit and for 
Brachyspira spp. at Veterinary Bacteriology and Pathology Unit. The current (October 2019) epidemiological 
cut-off (ECOFF) values were used to separate the wild-type population (referred as susceptible) from non-
wild-type isolates (referred as resistant) (Table 28). When available, clinical breakpoints of the current CLSI 
documents (CLSI VET08, 2018 or CLSI M100, 2019) were used to evaluate clinical resistance. There are no 
standardised breakpoints approved for Brachyspira spp. from swine. Clinical cut-off values (Rønne at al. 1990) 
were applied to B. pilosicoli MICs.   
 
Table 29. Epidemiological cut-off values (mg/L) used in this report. 
Substance 
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Ampicillin >8 >8    
Cefotaxime >0.5 >0.25    
Cefoxitin     >4 
Ceftazidime >2 >0.5    
Chloramphenicol >16 >16    
Ciprofloxacin >0.06 >0.06 >0.5 >0.5  
Colistin >2 1 >2    
Enrofloxacin  0,125    
Erythromycin   >4 >8  
Florfenicol >16 >16    
Gentamicin >2 >2 >2 >2  
Kanamycin  >2    
Meropenem >0.125 >0.125    
Nalidixic acid >16 >16 >16 >16  
Oxacillin     >2 
Streptomycin >16 >16 >4 >4  
Sulfamethoxazole >256 1 >64    
Tetracycline >8 >8 >1 >2 >1 
Trimethoprim >2 >2    
Trimethoprim/sulfamethoxazole2  >1   >0.5 
1 no ECOFF available 
2 concentration of trimethoprim given, concentration ratio with sulfamethoxazole 1:20 
 
Bacteria from companion animals 
 
Susceptibility testing of bacteria isolated from companion animals was performed in in the clinical 
microbiology laboratory of the Faculty of Veterinary Medicine with a disk diffusion technique with an 
available CLSI standard (CLSI VET01-A4). For all data, clinical breakpoints of the standard CLSI VET01-S2 was 
used to calculate non-susceptibility percentages. Resistance percentages include resistant and intermediate 
isolates. If veterinary breakpoints were not available, the breakpoints available in CLSI M100-S24 (2014) were 
used. An exception was the fucidic acid non-susceptibility breakpoint, which was ≤ 23 (FiRe-standard, version 
6). Beta-lactamase activity was tested with CefinaseTM disks (Becton Dickinson, NJ, USA). S. aureus with 
oxacillin or cefoxitin MIC values >2 or >4, respectively, were tested for the presence of the mecA gene with 
polymerase chain reaction (PCR) using primers described in Murakami et al. (1991). 
 
Quality assurance system 
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The Veterinary Bacteriology and Pathology Unit of the former Finnish Food Safety Authority, currently Finnish 
Food Authority participates in external quality assurance programmes for veterinary pathogens and in 
proficiency tests on isolation, identification and serotyping of Salmonella, and the Microbiology Unit 
participates in proficiency tests for antimicrobial susceptibility testing.  
 
For susceptibility tests the following bacteria were included as quality controls on at least a weekly basis: 
E. coli ATCC 25922, S. aureus ATCC 29213, C. jejuni ATCC 33560, Actinobacillus pleuropneumoniae ATCC 
27090 and Histophilus somni ATCC 700025. For Brachyspira susceptibility test, Brachyspira hyodysenteriae 
ATCC 31212 was used as a quality control strain. 
 
The Veterinary Bacteriology and Pathology Unit is accredited for isolation, identification and serotyping of 
salmonella, and the Microbiology Unit and the Bacteriology laboratory in Seinäjoki using VetMICTM and/or 
SensititreTM susceptibility panels in the susceptibility testing according to SFS-EN ISO/IEC 17025, by the 
Finnish Centre for Metrology and Accreditation. 
 
The clinical microbiology laboratory of the Faculty of Veterinary Medicine laboratory has internal quality 
control scheme with ATCC control strains; the quality control tests are performed on a weekly basis. In 
addition, the laboratory participates in several external quality control schemes (including identification and 
susceptibility testing of bacteria) organised by Labquality and VETQAS.   
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Appendix 4. Salmonella serovars isolated from food-producing animals in 2018 
 
Table 30. Salmonella enterica serovars isolated from the main food-producing animal species in Finland in 2018. 
Serotype 
Nr of 
isolates 
Cattle Pigs 
Poultry 
(Gallus 
gallus) 
Turkeys 
S. Typhimurium 22 15 6 1  
S. Enteritidis 6 5 1   
S. Kentucky 4 4    
S. Konstanz 2 2    
S. Senftenberg 2 2    
S. Tennessee 1 1    
S. Chester 1 1    
S. Newport 1 1    
S. Derby 1  1   
S. Montevideo 1  1   
S. Hessarek 1  1 (carcass)   
S. Hvittingfoss 1   1  
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